Oral nanomaterial formulations for gastrointestinal therapeutics: Promises and challenges on the path to clinical translation
Nano Biomedicine and Engineering · 2026-06 · 18 (2) · 100041
DOI: 10.1016/j.nbe.2025.100041 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nano Biomedicine and Engineering, 2026-06. Verfasst von Zehang Zhang und 6 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, National Science Fund for Distinguished Young Scholars.
Abstract (Originalsprache)
The gastrointestinal (GI) tract is an important route of drug delivery in the human body, offering advantages such as ease of administration, high patient compliance, and systemic delivery or targeted therapeutics. Nanomaterials have emerged as promising carriers for oral GI drug delivery due to their unique physicochemical properties, enabling enhanced drug solubility, protection against harsh GI environments, and targeted delivery to specific intestinal sites. These nanomaterials include both metallic and non-metallic materials. Metallic nanomaterials, such as titanium dioxide, gold, silver, copper, and zinc nanomaterials, exhibit potent antimicrobial activity, high stability, and the potential for controlled drug release. In contrast, non-metallic nanomaterials, including silica, polymer nanoparticles, carbon nanomaterials, liposomes, and selenium nanoparticles (SeNPs), offer improved biocompatibility, tunable biodegradability, and functional versatility for drug encapsulation and targeted GI therapy. However, their clinical translation is challenged by concerns over long-term safety, possible cytotoxicity, and regulatory barriers for large-scale production. Therefore, this article briefly outlines the application prospects of metallic and non-metallic nanomaterials in the GI, as well as the challenges that need to be overcome in the future, in order to promote the translational application of nanomaterials as oral formulations.
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- National Science Fund for Distinguished Young Scholars
Zitieren
APA
Zhang, Z., Lai, H., Liu, T., Yu, W., Yang, Y., Chen, T., & Huang, H. (2026). Oral nanomaterial formulations for gastrointestinal therapeutics: Promises and challenges on the path to clinical translation. Nano Biomedicine and Engineering, 18(2), 100041. https://doi.org/10.1016/j.nbe.2025.100041
Vancouver
Zhang Z, Lai H, Liu T, Yu W, Yang Y, Chen T, et al. Oral nanomaterial formulations for gastrointestinal therapeutics: Promises and challenges on the path to clinical translation. Nano Biomedicine and Engineering. 2026;18(2):100041. doi:10.1016/j.nbe.2025.100041
BibTeX
@article{Zhang2026,
author = {Zhang, Zehang and Lai, Haoqiang and Liu, Ting and Yu, Wenfang and Yang, Yu and Chen, Tianfeng and Huang, Hongwei},
title = {Oral nanomaterial formulations for gastrointestinal therapeutics: Promises and challenges on the path to clinical translation},
journal = {Nano Biomedicine and Engineering},
year = {2026},
volume = {18},
number = {2},
pages = {100041},
doi = {10.1016/j.nbe.2025.100041}
}
EUVIMED